Modulus Discovery rakes in $7.2M series A to fund R&D by Joseph Keenan Monday, August 13, 2018 Japan-based Modulus Discovery raised $7.2 million in series A funds that will be used to bolster its R&D platform efforts.
After its recent funding round, HiFiBiO pens Takeda R&D collab by Ben Adams Monday, July 30, 2018 HiFiBiO Therapeutics has signed a deal with Japanese Big Pharma and biotech friend Takeda to work on antibody therapies.
Astellas pledges $102.5M for universal donor cell company by Phil Taylor Wednesday, February 14, 2018 Astellas has bought out a U.S. biotech that wants to ensure cell therapy products aren’t rejected by a patient’s immune system.
Sirtuin enzyme could point to new therapies for diabetes and obesity by Arlene Weintraub Monday, January 29, 2018 Sirt2, an enzyme long of interest to scientists studying metabolism and aging, seems to mediate the process by which the liver processes glucose.
Takeda hands over $150M to Denali for neurodegenerative work by Ben Adams Friday, January 5, 2018 Takeda has struck two deals this morning as it looks to make good on its ongoing R&D reorganization.
Bristol-Myers boosts I-O offering with new Ono drug deal by Ben Adams Thursday, December 14, 2017 Bristol-Myers Squibb has licensed a phase 1 immuno-oncology drug from Japan’s Ono in a $40 million upfront pact.
Bayer signs another $1B R&D pact by Ben Adams Monday, November 20, 2017 Bayer has signed a potentially major research pact with Japan’s PeptiDream, marking the second big biobucks deal for the German pharma in the past week.
Daiichi posts rare cancer data from suspended ENLIVEN test by Ben Adams Tuesday, October 31, 2017 A year ago, Daiichi and partner Plexxikon suspended a trial of a rare cancer candidate on safety advice. Today they posted some very top-line results.
Clinigen buys Japan's largest supplier of unlicensed medicines by Angus Liu Monday, October 23, 2017 A year after launching its Japanese business, Clinigen has bought Japan’s largest supplier of unlicensed medicines.
